2835bce2-bf08-41a7-98b4-f488159b2685
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- OXIDATIVE_PHOSPHORYLATION+0.500
- G2M_CHECKPOINT+0.400
- CHOLESTEROL_HOMEOSTASIS+0.300
- DNA_REPAIR+0.300
- FATTY_ACID_METABOLISM+0.300
- GLYCOLYSIS+0.300
- MITOTIC_SPINDLE+0.200
- MTORC1_SIGNALING+0.200
- MYC_TARGETS_V1+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- INTERFERON_ALPHA_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- IL6_JAK_STAT3_SIGNALING-0.400
- ANGIOGENESIS-0.300
- INFLAMMATORY_RESPONSE-0.300
- KRAS_SIGNALING_DN-0.300
- KRAS_SIGNALING_UP-0.300
- COMPLEMENT-0.200
- IL2_STAT5_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 49319954-0844-4fbc-a931-df0e4cdbcb14 | — | — | 0.911 |
| 2 | s0112308 | — | — | 0.892 |
| 3 | s0094236 | — | — | 0.878 |
| 4 | TCGA-21-1075-01A-01R-0692-07 | — | cohortSQ2 | 0.877 |
| 5 | SRR4296106 | — | cohortSQ1 | 0.875 |
| 6 | s0112311 | — | — | 0.871 |
| 7 | TCGA-EW-A2FW-01A-11R-A17B-07 | — | B | 0.867 |
| 8 | SRR6013533 | — | cohortSQ2 | 0.866 |
| 9 | TCGA-B6-A0X5-01A-21R-A109-07 | — | B | 0.865 |
| 10 | SRR5088895 | — | — | 0.864 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |